



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/537,642	12/27/2005	Alessandro Sette	EPI.103X	5117
23557	7590	05/14/2010		
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO Box 142950 GAINESVILLE, FL 32614				
			EXAMINER	
			TONGUE, LAKIA J	
			ART UNIT	PAPER NUMBER
			1645	
NOTIFICATION DATE	DELIVERY MODE			
05/14/2010	ELECTRONIC			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

cuspto@slspatents.com

Office Action Summary	Application No. 10/537,642	Applicant(s) SETTE ET AL.
	Examiner LAKIA J. TONGUE	Art Unit 1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 26 January 2010.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 45-65 is/are pending in the application.
 4a) Of the above claim(s) 65 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 45-64 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

1. Applicant's amendment filed on January 26, 2010 is acknowledged. Claims 45-65 are pending. Claims 66-69 have been canceled. Claim 65 was previously withdrawn. Claims 45, 50, 55 and 60 have been amended. Claims 45-64 are currently under examination.

Rejections Maintained

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. The rejection of claims 45-50, 52-60 and 62-64 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement because the claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention is maintained for the reasons set forth in the previous office action. The cancellation of claims 66-69 renders the rejection of said claims moot.

Applicants argue that:

1) The influence of protein folding on antibody-antigen interactions is not relevant to the binding requirements of HLA binding peptides.

2) Claims 45, 50, 55 and 60 have been amended to recite that the HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids, which obviates the stated ground of rejection.

3) The claimed HLA binding fragments constitute a well defined number of peptides which can be directly excised from SEQ ID NO: 1.

4) The provision of the entire sequence of SEQ ID NO: 1 provides the necessary starting point for a very simple test where fragments are assayed for their binding to HLA molecules.

5) The specification conveys with reasonable clarity to those of ordinary skill in the art that, as of the applications date, Applicants were in possession of the claimed subject matter.

Applicant's arguments have been considered but are deemed non-persuasive.

The rejected claims are drawn to an isolated or purified polynucleotide: a) encoding a polypeptide comprising SEQ ID NO: 1; b) encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, wherein said fragment comprises at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids; or c) that is complementary along the full length of said polynucleotide of a) or b). Subsequent claims are drawn to a vector comprising a promoter operably linked to a polynucleotide and a transformed host cell comprising a polynucleotide: a) encoding a polypeptide comprising SEQ ID

NO: 1; b) encoding a HLA binding fragment of SEQ ID NO: 1, wherein said fragment comprises at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids; or c) that is complementary to the polynucleotide of a) or b).

With regard to Points 1 and 2, while the claims are drawn to an isolated or purified polynucleotide as identified above. Contrary to Applicant's assertion, the influence of protein folding interactions is relevant to the binding requirement of HLA binding peptides. While Greenspan et al. and other references tend to focus on antibody binding peptides, the skilled artisan cannot envision the detailed chemical structure of the claimed polynucleotides or the binding fragment which will encodes a Human Leukocyte Antigen (HLA) of SEQ ID NO: 1, wherein said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids. The core structure has not been identified, consequently, which fragment will bind appropriately is unknown. The claims encompass a genus of polynucleotides which are to be encoded by said polypeptides and binding fragments, which are not adequately described. Since the amino acid sequence of the polypeptide determines its structural and functional properties, predictability of which changes can be tolerated in a polypeptide's amino acid sequence and still retain similar activity requires a knowledge with regard to which amino acids in the polypeptide's sequence, if any, are tolerant of modification and which are conserved

(i.e. expected intolerant to modification) and detailed knowledge of the ways in which the polypeptide's structure relates to function.

With regard to Points 3-5, the specification provides written description for an isolated or purified polynucleotide, which encodes a polypeptide comprising SEQ ID NO: 1, however the specification lacks written description for an isolated polynucleotide encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids; a fragment that is complementary along the full length of said polynucleotide; a vector comprising a promoter operably linked to a polynucleotide and a transformed host cell comprising a polynucleotide: a) encoding a polypeptide comprising SEQ ID NO: 1; b) encoding a HLA binding fragment of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids.; or c) that is complementary to the polynucleotide of a) or b). While the specification fully represents SEQ ID NO: 1, a skilled artisan would not appreciate that Applicants were in possession of an isolated purified polynucleotide encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids.; or c) that is complementary along the full length of said polynucleotide

of a) or b). Moreover, written description *requires possession of that which has been claimed, not just the means of isolation.* Based on the instant specification, the skilled artisan cannot envision the detailed chemical structure of the claimed polynucleotide. The specification fails to provide any additional representative species of the claimed genus to show that applicant was in possession of the claimed genus.

As previously presented, to fulfill the written description requirements set forth under 35 USC § 112, first paragraph, the specification must describe at least a substantial number of the members of the claimed genus of polynucleotides or alternatively describe a representative member of the claimed genus, which shares a particularly defining feature common to at least a substantial number of the members of the claimed genus, which would enable the skilled artisan to immediately recognize and distinguish its members from others, so as to reasonably convey to the skilled artisan that Applicant has possession of the claimed invention.

A representative number of species means that the species which are adequately described are representative of the entire genus. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, disclosure of drawings, or by disclosure of relevant identifying characteristics, for example, structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus.

The specification lacks a full description of which polynucleotide, vector and transformed host cell comprising a polynucleotide will encode any HLA binding fragment of SEQ ID NO: 1 or its complementary polynucleotide. The specification is silent with regard to which specific immunoepitopes are capable of encoding any HLA binding fragment of SEQ ID NO: 1 or its complementary polynucleotide. The specification discloses SEQ ID NO: 1, but does not provide structure correlated with function.

As evidenced by Greenspan et al. (*Nature Biotechnology* 17: 936-937, 1999), defining epitopes is not as easy as it seems. Greenspan et al. recommends defining an epitope by the structural characterization of the molecular interface between the antigen and the antibody is necessary to define an "epitope" (page 937, column 2). According to Greenspan et al., an epitope will include residues that make contacts with a ligand, here the antibody, but are energetically neutral, or even destabilizing to binding. Furthermore, an epitope will not include any residue not contacted by the antibody, even though substitution of such a residue might profoundly affect binding. Accordingly, it follows the epitope to which any given antibody binds can only be identified empirically. Even using a competition assay, the skilled artisan cannot determine whether an antibody binds the same epitope as another antibody because an antibody that competes with another does not necessarily bind the same epitope as the other; rather, one antibody may bind a spatially overlapping epitope to sterically hinder binding of the other.

The skilled artisan cannot envision the detailed chemical structure of the claimed isolated or purified polynucleotide, which encodes a HLA binding fragment of SEQ ID NO: 1 or its complementary polynucleotide. The specification fails to provide any additional representative species of the claimed genus to show that applicant was in possession of the claimed genus. Adequate written description requires more than a mere statement that it is part of the invention. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. In *Fiddes v. Baird*, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

The University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404. 1405 held that: ...To fulfill the written description requirement, a patent specification must describe an invention and does so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines Inc.* , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli* , 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he

description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention."

Lockwood, 107 F.3d at 1572, 41 USPQ2d at 966.

Further, Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the *invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116). The skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore, conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993).

Therefore, for all these reasons the specification lacks adequate written description, and one of skill in the art cannot reasonably conclude that the applicant had possession of the claimed invention at the time the instant application was filed.

Claim Rejections - 35 USC § 102

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. The rejection of claims 45, 47, 50, 52, 55, 57, 60 and 62 under 35 U.S.C. 102(b) as being anticipated by Hoffman et al. (WO 00/25728) is maintained for the reasons set forth in the previous office action.

Applicant argues that:

1) SEQ ID NO: 112 of the Hoffman et al. publication is 1,817 amino acids in length; therefore, the Hoffman publication does not disclose the HLA binding fragment recited in the claims as currently amended.

Applicant's arguments have been considered and are deemed non-persuasive.

The rejected claims are drawn to an isolated or purified polynucleotide: a) encoding a polypeptide comprising SEQ ID NO: 1; b) encoding a Human Leukocyte Antigen binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids; or c) that is complementary along the full length of said polynucleotide of a) or b).

With regard to Point 1, Applicant's claimed invention has been identified above. The Hoffman publication discloses an isolated or purified polynucleotide: encoding a Human Leukocyte Antigen binding *fragment* of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids. While the sequence of Hoffman is 1,817 amino acids, a fragment of SEQ ID NO: 1 does not have to be and is not

necessarily the full length of SEQ ID NO: 1, which is 1,904 amino acids. It can be any fragment thereof that comprises at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids.

As previously presented, Hoffman et al. disclose whole genes and the portions of the DNA that constitute protein-encoding genes (see page 2, lines 16-17). Hoffman et al. disclose *P. falciparum* DNA that has been cloned into DNA vaccines, which is a plasmid vector designed to express the cloned fragment when injected into human or animal tissue. The polypeptides will then be taken up by antigen presenting cells and the host immune system will respond by producing either cellular or humoral immune responses directed at each of the expressed polypeptides (see page 13, lines 22-27). Moreover, Hoffman et al. disclose SEQ ID NO: 112, which according to STIC has 5 consecutive amino acids of SEQ ID NO: 1 (see SEQ ID NO: 112, pages 241-246).

Since the Office does not have the facilities for examining and comparing applicants' composition with the composition of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

4. The rejection of claims 45, 47, 50, and 52 under 35 U.S.C. 102(a) as being anticipated by Gardner et al. (Nature, 2002; 419: 498-511) is maintained for the reasons set forth in the previous office action.

Applicant argues that:

1) The cited portions of the Gardner et al. publication do not appear to disclose a polynucleotide encoding an HLA binding fragment of SEQ ID NO: 1, and respectfully

submit that the presence of inherent matter must be grounded on more than speculation, it must be certainty.

Applicant's arguments have been considered and are deemed non-persuasive.

The rejected claims are drawn to an isolated or purified polynucleotide: a) encoding a polypeptide comprising SEQ ID NO: 1; b) encoding a Human Leukocyte Antigen binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 1 and has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 21, 32, 33, 34, and 35 amino acids; or c) that is complementary along the full length of said polynucleotide of a) or b).

With regard to Point 1, contrary to Applicant's assertion, the Examiner's position with regard to the Gardner et al. publication is not grounded on inherency and speculation. While, Gardner et al. do not physically disclose the HLA binding fragment of SEQ ID NO: 1, SEQ ID NO: 1 is anticipated by the Gardner et al. publication. This is evidenced by the SCORE alignment print out which has been attached to this office action and is entitled "STIC Search SEQ ID NO 1 Alignment". Said alignment depicts the claimed sequence, when it was submitted and clearly discloses that SEQ ID NO: 1 is a part of the Gardner et al. publication.

As previously presented, Gardner et al. disclose an isolated or purified polynucleotide encoding an antigen binding fragment of SEQ ID NO: 1 comprising at least five consecutive amino acids of SEQ ID NO: 1 (evidenced in the STIC report; see Gardner et al.-title and page 501). Gardner et al. disclose the use of a vector to support the development, deployment and monitoring of malaria control methods (see page 508; concluding remarks).

Since the Office does not have the facilities for examining and comparing applicants' composition with the composition of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

Conclusion

5. No claims are allowed.

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J. TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached on Monday-Friday 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT
5/8/10

/Robert B Mondesi/
Supervisory Patent Examiner, Art Unit 1645